Replacing PEG with PCB in lipid nanoparticles led to potent mRNA vaccines that avoided unwanted immune responses.

The Trump administration has canceled $766 million awarded to drugmaker Moderna Inc. to develop a vaccine against potential ...

Population-adjusted indirect comparison (PAIC) of avelumab (AVE) and retifanlimab (RETI) in the first-line (1L) treatment of patients (pts) with metastatic Merkel cell carcinoma (mMCC). Survival ...

LNP development has been a headache, but without this packaging, mRNA vaccines would be nothing. “It is the unsung hero of the whole thing,” says Giuseppe Ciaramella, who was head of ...

GenScript, a global leader in life science research tools and services support, has expanded its mRNA synthesis and ...

Acuitas’ LNP enabled delivery of three doses of a personalized CRISPR therapy with no adverse events to an infant patient with severe urea cycle disorder Athebody® DARPin-conjugated LNP resulted in ...

The therapy was composed of an mRNA encoding a CRISPR enzyme and guide RNA, encapsulated in Acuitas’ LNP formulation composed of ionizable lipid ALC-0307™ and PEG-lipid ALC-0159™.

Lipid nanoparticle (LNP) mRNA vaccines emerged during the COVID-19 pandemic to form an almost miraculous protection against a virus, which killed millions around the world. Aided by expedited ...